The Israeli company Restore Medical has published the first results of a clinical trial in which it implanted its product, ContraBand, designed to treat heart congestion for the first time in humans. The product is implanted in a minimally invasive procedure, using a catheter, and is designed to treat patients with chronic left ventricular failure, where the heart is unable to pump enough oxygen-rich blood to through the body. It brings the healthy right ventricle to help the failing left ventricle, so that patients experience relief from their symptoms and further damage to the heart is avoided.
Congestive heart failure is a progressive and debilitating disease and one of the leading causes of death. Less than half of patients survive five years after diagnosis, and only 30% survive ten years. 25% of patients return to hospital within one month of discharge, which is also the leading cause of repeat hospitalizations. The disease affects tens of millions of people worldwide, including 6.2 million in the United States alone, and it is considered the greatest unmet clinical and financial need facing global health systems.
Restore Medical has successfully implanted the ContraBand device in five patients at ZNA Medical Center in Middelheim, Antwerp, Belgium and Kaplan Medical Center in Israel.
The company is led by CEO Gilad Marom and was established in 2015 by Dr Elchanan Bruckheimer (Medical Director), Aaron Feldman (Member of the Board of Directors) and Stephen Bellomo (VP, Clinical Affairs). The main investors are Incentive Incubator, Peregrine Ventures, Allegro and an undisclosed strategic investor.
âThe positive impact this treatment can have on the millions of people with CHF cannot be underestimated. Not only will it transform the quality of life of treated patients, but it will also reduce the enormous financial burden that results from having patients under treatment, âsaid Marom.
Posted by Globes, Israel business news – en.globes.co.il – December 23, 2021.
Â© Copyright of Globes Publisher Itonut (1983) Ltd., 2021.